Evolving concepts in left ventricular systolic and diastolic remodeling: Implications for therapy

Current Cardiology Reports

Volumn 6, Issue 3, 2004, Pages 200-204

  Tang, W H Wilson ^a   Francis, Gary S ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENKEPHALINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYOSIN HEAVY CHAIN; NEUROHORMONE; NORADRENALIN; OXIPURINOL; RENIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASOPRESSIN RECEPTOR ANTAGONIST; CARDIOVASCULAR AGENT;

ARTIFICIAL HEART PACEMAKER; BIOCHEMISTRY; CHOLINERGIC SYSTEM; CYTOTOXICITY; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEART ARRHYTHMIA; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HUMAN; HYPOTHESIS; INOTROPISM; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYMPATHETIC TONE; DIASTOLE; DRUG EFFECTS; HEART VENTRICLE REMODELING; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES; SYSTOLE; TRENDS;

CARDIOVASCULAR AGENTS; DIASTOLE; HEART FAILURE; HUMANS; MOLECULAR TARGETED THERAPY; SYSTOLE; VENTRICULAR REMODELING;

EID: 3142671326     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0024-9     Document Type: Review

References (36)

1. Francis GS, Tang WH: Pathophysiology of congestive heart failure. Rev Cardiovasc Med 2003, 4:S14-S20.
2. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000, 35:569-582.
3. Metra M, Nodari S, Parrinello G, et al.: Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 2003, 145:292-299.
4. Kawai K, Takaoka H, Hata K, et al.: Prevalence, predictors and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 1999, 84:671-676.
5. Tang WHW, Larson MS, Prikazsky L, et al.: Reversal remodeling following long-term carvedilol therapy is associated with improvement in survival: the Stanford carvedilol echocardiographic registry [abstract]. J Am Coll Cardiol 2002, 39:141A.
6. Konstam MA, Udelson JE, Anand IS, et al.: Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail 2003, 9:350-353.
7. Morgan HE, Baker KM: Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation 1991, 83:13-25.
8. Katz AM: Maladaptive growth in the failing heart: the cardiomyopathy of overload. Cardiovasc Drug Ther 2002, 16:245-249.
9. Francis GS, McDonald KM, Cohn JN: Neurohormoral activation in preclinical heart failure. Remodeling and the potential for intervention. Circulation 1993, 87:IV90-IV96.
10. Dalby MCD, Burke M, Radley-Smith R, et al.: Pheochromocytoma presenting after cardiac transplantation for dilated cardiomyopathy. J Heart Lung Transplant 2001, 20:773-775.
11. Greenberg B, Quinones MA, Koilpillai C, et al.: Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995, 91:2573-2581.
12. Konstam MA, Kronenberg MW, Rousseau MF, et al.: Effects of angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993, 88:2277-2283.
13. Cuspidi C, Muiesan ML, Valagussa L, et al.: Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002, 20:2203-2300.
14. McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056-1064.
15. Wachtell K, Dahlof B, Rokkedal J, et al.: Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am Heart J 2002, 144:1057-1064.
16. McKelvie RS, Rouleau JL, White M, et al.: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J 2003, 24:1727-1734.
17. Hayashi M, Tsutamoto T, Wada A, et al.: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003, 107:2559-2565.
18. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
19. Lowes BD, Gill EA, Abraham WT, et al.: Effects of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure. Am J Cardiol 1999, 83:1201-1205.
20. Wong M, Staszewsky L, Latini R, et al.: Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002, 40:970-975.
21. Schleman KA, Lindenfeld JA, Lowes BD, et al.: Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail 2001, 7:4-12.
22. Tang WH, Francis GS: Novel pharmacological treatments for heart failure. Expert Opin Investig Drugs 2003, 12:1791-1801.
23. Mann DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988-998.
24. Mann DL, Taegtmeyer H: Dynamic regulation of the extracellular matrix after mechanical unloading of the failing human heart. Recovering the missing link in left ventricular remodeling. Circulation 2001, 104:1089-1091.
25. Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993, 27:341-348.
26. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circ Res 1991, 83:1849-1865.
27. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
28. Zannad F, Dousset B: Treatment of congestive heart failure. Interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001, 38:1227-1232.
29. Taegtmeyer H, McNulty P, Young ME: Adaptation and maladaptation of the heart in diabetes. Part I: general concepts. Circulation 2002, 105:1727-1733.
30. Young ME, McNulty P, Taegtmeyer H: Adaptation and maladaptation of the heart in diabetes. Part II: potential mechanisms. Circulation 2002, 105:1861-1870.
31. Dyntar D, Eppenberger-Eberhardt M, Maedler K, et al.: Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 2001, 50:2105-2113.
32. Del Monte F, Johnson CM, Stepanek AC, et al.: Defects in calcium control. J Card Fail 2002, 8:S421-S431.
33. St John Sutton MG, Plappert T, Abraham WT, et al.: Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003, 107:1985-1990.
34. Le Corvoisier P, Park HY, Rockman HA: Modifier genes and heart failure. Minerva Cardioangiol 2003, 51:107-120.
35. Liao Y, Cooper RS, McGee DL, et al.: The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995, 273:1592-1597.
36. Houghton JL, Prisant LM, Carr AA, et al.: Racial differences in myocardial ischemia and coronary flow reserve in hypertension. J Am Coll Cardiol 1994, 23:1123-1129.